172 related articles for article (PubMed ID: 38502703)
1. Mimicking angiogenic microenvironment of alveolar soft-part sarcoma in a microfluidic coculture vasculature chip.
Chuaychob S; Lyu R; Tanaka M; Haginiwa A; Kitada A; Nakamura T; Yokokawa R
Proc Natl Acad Sci U S A; 2024 Mar; 121(13):e2312472121. PubMed ID: 38502703
[TBL] [Abstract][Full Text] [Related]
2. Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma.
Castelli C; Tazzari M; Negri T; Vergani B; Rivoltini L; Stacchiotti S; Pilotti S
J Transl Med; 2013 Sep; 11():237. PubMed ID: 24074204
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
Paoluzzi L; Maki RG
JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
[TBL] [Abstract][Full Text] [Related]
4. Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy.
Soheilifar MH; Taheri RA; Zolfaghari Emameh R; Moshtaghian A; Kooshki H; Motie MR
Biomed Pharmacother; 2018 Jul; 103():889-896. PubMed ID: 29710505
[TBL] [Abstract][Full Text] [Related]
5. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A
Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710
[TBL] [Abstract][Full Text] [Related]
6. ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma.
Tanaka M; Chuaychob S; Homme M; Yamazaki Y; Lyu R; Yamashita K; Ae K; Matsumoto S; Kumegawa K; Maruyama R; Qu W; Miyagi Y; Yokokawa R; Nakamura T
Nat Commun; 2023 Apr; 14(1):1957. PubMed ID: 37029109
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib and dastinib exert anti-tumor activity in alveolar soft part sarcoma.
Mukaihara K; Tanabe Y; Kubota D; Akaike K; Hayashi T; Mogushi K; Hosoya M; Sato S; Kobayashi E; Okubo T; Kim Y; Kohsaka S; Saito T; Kaneko K; Suehara Y
PLoS One; 2017; 12(9):e0185321. PubMed ID: 28945796
[TBL] [Abstract][Full Text] [Related]
8. Modeling Alveolar Soft Part Sarcoma Unveils Novel Mechanisms of Metastasis.
Tanaka M; Homme M; Yamazaki Y; Shimizu R; Takazawa Y; Nakamura T
Cancer Res; 2017 Feb; 77(4):897-907. PubMed ID: 27979841
[TBL] [Abstract][Full Text] [Related]
9. iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study.
Mcaddy NC; Saffar H; Litière S; Jespers P; Schöffski P; Messiou C
Cancer Imaging; 2020 Oct; 20(1):79. PubMed ID: 33121537
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
11. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies.
Groisberg R; Roszik J; Conley AP; Lazar AJ; Portal DE; Hong DS; Naing A; Herzog CE; Somaiah N; Zarzour MA; Patel S; Brown RE; Subbiah V
Mol Cancer Ther; 2020 May; 19(5):1165-1172. PubMed ID: 32127467
[TBL] [Abstract][Full Text] [Related]
12. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
[TBL] [Abstract][Full Text] [Related]
13. ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.
Kenney S; Vistica DT; Stockwin LH; Burkett S; Hollingshead MG; Borgel SD; Butcher DO; Schrump DS; Shoemaker RH
J Pediatr Hematol Oncol; 2011 Jul; 33(5):360-8. PubMed ID: 21552147
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma.
Lazar AJ; Das P; Tuvin D; Korchin B; Zhu Q; Jin Z; Warneke CL; Zhang PS; Hernandez V; Lopez-Terrada D; Pisters PW; Pollock RE; Lev D
Clin Cancer Res; 2007 Dec; 13(24):7314-21. PubMed ID: 18094412
[TBL] [Abstract][Full Text] [Related]
15. Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study.
Fujiwara T; Nakata E; Kunisada T; Ozaki T; Kawai A
BMC Cancer; 2022 Aug; 22(1):891. PubMed ID: 35971085
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial.
Lee CJ; Modave E; Boeckx B; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Debiec-Rychter M; Sciot R; Lambrechts D; Wozniak A; Schöffski P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628499
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.
Brahmi M; Vanacker H; Dufresne A
Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316
[TBL] [Abstract][Full Text] [Related]
18. Modeling alveolar soft part sarcomagenesis in the mouse: a role for lactate in the tumor microenvironment.
Goodwin ML; Jin H; Straessler K; Smith-Fry K; Zhu JF; Monument MJ; Grossmann A; Randall RL; Capecchi MR; Jones KB
Cancer Cell; 2014 Dec; 26(6):851-862. PubMed ID: 25453902
[TBL] [Abstract][Full Text] [Related]
19. Advanced alveolar soft part sarcoma responds to apatinib.
Zhou Y; Tang F; Wang Y; Min L; Luo Y; Zhang W; Shi R; Duan H; Tu C
Oncotarget; 2017 Jul; 8(30):50314-50322. PubMed ID: 28679123
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma.
Kim M; Kim TM; Keam B; Kim YJ; Paeng JC; Moon KC; Kim DW; Heo DS
Oncologist; 2019 Jan; 24(1):20-e29. PubMed ID: 30254189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
